- Home
- FONR vs CRBP Comparison
FONR vs CRBP Comparison
Compare FONR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FONR
- CRBP
- Stock Information
- Founded
- FONR 1978
- CRBP 2009
- Country
- FONR United States
- CRBP United States
- Employees
- FONR N/A
- CRBP N/A
- Industry
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- FONR Health Care
- CRBP Health Care
- Exchange
- FONR Nasdaq
- CRBP Nasdaq
- Market Cap
- FONR 77.1M
- CRBP 73.4M
- IPO Year
- FONR 1987
- CRBP N/A
- Fundamental
- Price
- FONR $14.18
- CRBP $8.33
- Analyst Decision
- FONR
- CRBP Strong Buy
- Analyst Count
- FONR 0
- CRBP 10
- Target Price
- FONR N/A
- CRBP $53.56
- AVG Volume (30 Days)
- FONR 31.0K
- CRBP 120.9K
- Earning Date
- FONR 05-15-2025
- CRBP 08-05-2025
- Dividend Yield
- FONR N/A
- CRBP N/A
- EPS Growth
- FONR N/A
- CRBP N/A
- EPS
- FONR 1.28
- CRBP N/A
- Revenue
- FONR $103,018,089.00
- CRBP N/A
- Revenue This Year
- FONR N/A
- CRBP N/A
- Revenue Next Year
- FONR N/A
- CRBP $150.03
- P/E Ratio
- FONR $11.01
- CRBP N/A
- Revenue Growth
- FONR 0.29
- CRBP N/A
- 52 Week Low
- FONR $12.00
- CRBP $4.64
- 52 Week High
- FONR $18.68
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- FONR 53.63
- CRBP 54.09
- Support Level
- FONR $14.10
- CRBP $8.10
- Resistance Level
- FONR $14.60
- CRBP $9.45
- Average True Range (ATR)
- FONR 0.38
- CRBP 0.52
- MACD
- FONR -0.10
- CRBP -0.08
- Stochastic Oscillator
- FONR 40.58
- CRBP 55.74
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.